PRMT5 and systemic sclerosis: Here, we first identified PRMT5 as a novel autoantibody target in SSc based on the automated deep efficient peptide sequencing and quantification (DEEP SEQ) mass spectrometry (MS) platform22 for the enriched antigen-antibody complex.